Scholar Rock Demonstrates that Highly Specific TGFβ1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade Therapy
09 nov. 2018 08h00 HE
|
Scholar Rock
Preclinical Data Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting Shows Highly Specific Inhibitor of TGFβ1, SRTβ1-Ab3, Renders Resistant Solid Tumors Vulnerable to PD1...
Scholar Rock to Present at the Jefferies 2018 London Healthcare Conference
31 oct. 2018 07h00 HE
|
Scholar Rock
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth...
Scholar Rock to Present Preclinical Data Highlighting the Role of TGFβ1 Inhibition in Overcoming Checkpoint Resistance at the SITC Annual Meeting
01 oct. 2018 17h06 HE
|
Scholar Rock
CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth...
Scholar Rock to Participate in Upcoming Investor Conferences
02 août 2018 09h00 HE
|
Scholar Rock
CAMBRIDGE, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth...
Scholar Rock Announces Exercise in Full and Closing of Over-Allotment Option in Initial Public Offering
04 juin 2018 07h00 HE
|
Scholar Rock
CAMBRIDGE, Mass., June 04, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ:SRRK), a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of...
Scholar Rock Announces Completion of Dosing of First Cohort in Phase 1 Clinical Trial of SRK-015
31 mai 2018 07h00 HE
|
Scholar Rock
CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ:SRRK), a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of...
Scholar Rock Announces Pricing of Initial Public Offering
23 mai 2018 21h52 HE
|
Scholar Rock
CAMBRIDGE, Mass., May 23, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ:SRRK), a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of...